Prof. Jin Xu 徐近
Chief Physician, Professor
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive and open surgery for benign and malignant pancreatic tumors. Resection of pancreatic, duodenal, ampullary, gallbladder, bile duct, splenic, and retroperitoneal tumors. Chemotherapy, targeted therapy, immunotherapy, and clinical trials for pancreatic cancer. Surgical management of pancreatic neuroendocrine tumors.
Dr. Xu is a Chief Physician, Professor, and doctoral supervisor. Dr. Xu serves as Director of the Department of Pancreatic Surgery and Director of the Department of Comprehensive Treatment of Pancreatic Tumors at Fudan University Shanghai Cancer Center. With over 20 years in pancreatic surgery, Dr. Xu performs more than 300 pancreatic tumor resections annually.
Professional roles
- Chair, Pancreatic Tumor Integrated Rehabilitation Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Pancreatic Cancer Professional Committee, China Anti-Cancer Association
- Member, Minimally Invasive Diagnosis and Treatment Group, Pancreatic Cancer Professional Committee, China Anti-Cancer Association
- Chair, Neuroendocrine Tumor Professional Committee, Shanghai Anti-Cancer Association
Name order: in Chinese the family name comes first (Xu Jin). Papers usually list the name as Jin Xu or Xu J.
Selected publications
198 papers on PubMed matched by name and affiliation; 19 as first or senior author since 2016. Most recent first- or senior-author papers:
- Transl Oncol, 2026 (senior author): GMPS drives pancreatic cancer progression via suppressing DNA damage, STING activation and cellular senescence. PubMed 42767098
- Cancer Med, 2026 (senior author): Genomic Alterations and Their Clinical Implications in Pancreatic Ductal Adenocarcinoma in a Large-Scale Chinese Cohort. PubMed 42487270
- BMC Cancer, 2025 (senior author): Constructing a machine learning model for predicting early postoperative recurrence of pancreatic head cancer based on a novel inflammatory factor composite index. PubMed 41469859
- Chin Med J (Engl), 2025 (senior author): SMUG1 promoted the progression of pancreatic cancer via AKT signaling pathway through binding with FOXQ1. PubMed 40789659
- Discov Oncol, 2025 (senior author): Identification of DNA damage and repair gene-related markers in pancreatic ductal adenocarcinoma by single-cell and bulk RNA sequencing. PubMed 40198431
- Transl Oncol, 2025 (senior author): The pancreatitis-cancer transformation-related factor, human rhomboid family-1, promotes pancreatic cancer progression through the SRC/YAP signaling pathway. PubMed 40056528
- Comput Struct Biotechnol J, 2023 (senior author): Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogeneity of PET-CT. PubMed 37153537
- Curr Oncol, 2023 (senior author): Cuproptosis-Related Gene DLAT as a Novel Biomarker Correlated with Prognosis, Chemoresistance, and Immune Infiltration in Pancreatic Adenocarcinoma: A Preliminary Study Based on Bioinformatics Analysis. PubMed 36975441
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion